Literature DB >> 8083563

Ganciclovir ophthalmic gel in herpes simplex virus rabbit keratitis: intraocular penetration and efficacy.

N Castela1, N Vermerie, F Chast, H Sauvageon-Martre, J Denis, V Godard, P Goldschmidt, Y Pouliquen.   

Abstract

A chronic administration of three ganciclovir gels (0.2%, 0.05%, 0.0125%) was compared with a placebo gel and a 3% acyclovir ophthalmic ointment in the treatment of HSV-1 rabbit keratitis. All the ganciclovir gels showed a clinical efficacy: a significant reduction of the corneal ulcer area, clouding and vascularization (p < 0.05) and a fast inhibition of HSV isolates into tear film with the 0.2% and 0.05% ganciclovir gels. However the efficacy was slower than using acyclovir ointment. No significant difference could be shown between the 0.2% and 0.05% ganciclovir gels or the 0.05% ganciclovir gel and the acyclovir treatment on viral isolation, when it was performed on pooled samples. The distribution of ganciclovir and acyclovir into the rabbit eyes (HPLC methods), were similar but markedly higher in solid tissues than ocular fluids. It might explain the recovery from tissue damages. The mean corneal ganciclovir concentrations were largely higher than ED 50 of ganciclovir for HSV-1. No toxicity was expected, due to very limited systemic availability. This study suggests a comparable activity on HSV-1 superficial keratitis between 0.05%, 0.2% ganciclovir gels and 3% acyclovir ointment. Higher concentration of ganciclovir gels are probably necessary in order to treat the HSV-1 kerato-uveitis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083563     DOI: 10.1089/jop.1994.10.439

Source DB:  PubMed          Journal:  J Ocul Pharmacol        ISSN: 8756-3320


  19 in total

1.  Controlled ocular delivery of acyclovir through rate controlling ocular insert of Eudragit: a technical note.

Authors:  Shagufta Khan; Asgar Ali; Dilesh Singhavi; Pramod Yeole
Journal:  AAPS PharmSciTech       Date:  2008-01-25       Impact factor: 3.246

2.  In vitro synergism of trifluorothymidine and ganciclovir against HSV-1.

Authors:  Jeffery A Hobden; Manish Kumar; Herbert E Kaufman; Christian Clement; Emily D Varnell; Partha S Bhattacharjee; James M Hill
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-11       Impact factor: 4.799

3.  Treatment outcome and risk factors for visual loss in Cytomegalovirus endotheliitis.

Authors:  Soon-Phaik Chee; Aliza Jap
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-03       Impact factor: 3.117

4.  Long-term oral therapy with valganciclovir in patients with Posner-Schlossman syndrome.

Authors:  B Sobolewska; C Deuter; D Doycheva; M Zierhut
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-28       Impact factor: 3.117

5.  Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes.

Authors:  Joseph Colin
Journal:  Clin Ophthalmol       Date:  2007-12

6.  Topical ganciclovir in the treatment of acute herpetic keratitis.

Authors:  Khalid F Tabbara; Noorjehan Al Balushi
Journal:  Clin Ophthalmol       Date:  2010-08-19

Review 7.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

8.  Cytomegalovirus-related corneal endotheliitis: A review article.

Authors:  Abdullah Alfawaz
Journal:  Saudi J Ophthalmol       Date:  2011-10-10

Review 9.  Pharmacologic strategies in the prevention and treatment of corneal transplant rejection.

Authors:  Khalid F Tabbara
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

10.  Effectiveness and safety of 0.15% ganciclovir in situ ophthalmic gel for herpes simplex keratitis - a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.

Authors:  Tong Lin; Lan Gong; Xing-Huai Sun; Nai-Qing Zhao; Wei Chen; Hui-Ping Yuan; Yan Shao; Ming-Hong Gao; Hai Tang
Journal:  Drug Des Devel Ther       Date:  2013-04-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.